LINC02946: A Non-Coding RNA Molecule as A Potential Drug Target

Target Name: LINC02946

NCBI ID: G285000

LINC02946

Other Name(s): RMEL1 | Long intergenic non-protein coding RNA 2946 | long intergenic non-protein coding RNA 2946

LINC02946: A Non-Coding RNA Molecule as A Potential Drug Target

LINC02946 is a non-coding RNA molecule that has been identified as a potential drug target (RMEL1) for the treatment of various diseases, including cancer. Its unique structure and biochemical properties make it an attractive target for drug development due to its ability to modulate gene expression and contribute to the development of diseases.

The RNA molecule LINC02946 is composed of 21 amino acid residues and has a unique 5'-end that consists of a conserved glycine-rich region and a unique 3'-end that is composed of a single amino acid, glutamic acid. This unique 3 '-end region is important for the stability and translation of the RNA molecule, and has been shown to play a role in the regulation of various cellular processes, including cell growth, apoptosis, and transcriptional regulation.

One of the key features of LINC02946 is its ability to interact with DNA and histone proteins. This interaction allows the RNA molecule to modulate gene expression by binding to specific DNA sequences and histone proteins, which in turn can alter the activity of gene-specific transcription factors. This mechanism of action is similar to that of other RNA molecules that have been identified as drug targets, such as RNA interference (RNAi) drugs, which use a similar mechanism to block the translation of specific genes.

Another important property of LINC02946 is its ability to form a complex with proteins that are involved in the regulation of cellular processes, including cell cycle progression, apoptosis, and angiogenesis. These protein-RNA interactions can modulate the activity of these proteins and contribute to the development of diseases. For example, LINC02946 has been shown to form a complex with the protein camouflage enzyme (p16), which is involved in the regulation of apoptosis. This complexation has been shown to alter the activity of p16 and contribute to the regulation of apoptosis.

In addition to its ability to interact with proteins, LINC02946 also has unique structural features that make it an attractive drug target. The 5'-end of the RNA molecule is conserved and has been shown to be involved in the stability and translation of the RNA molecule. This conserved region is a potential target for small molecules that can modulate the stability or translation of the RNA molecule.

The 3'-end of the LINC02946 molecule is also unique and has been shown to play a role in the regulation of gene expression. This region is composed of a single amino acid, glutamic acid, which is important for its stability and translation. This region is composed of a single amino acid, glutamic acid, which is important for its stability and translation. A single amino acid residue makes it an attractive target for small molecules that can modulate the stability or translation of the RNA molecule.

In conclusion, LINC02946 is a unique RNA molecule that has been identified as a potential drug target (RMEL1) due to its ability to modulate gene expression and contribute to the development of diseases. Its unique structure and biochemical properties make it an attractive target for drug development, and further studies are needed to determine its full potential as a therapeutic agent.

Protein Name: Long Intergenic Non-protein Coding RNA 2946

The "LINC02946 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02946 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets